Unfractionated heparin monitoring by anti-factor Xa versus activated partial thromboplastin time strategies during venoarterial extracorporeal life support

IntroductionNo clear guidelines exist for unfractionated heparin (UFH) monitoring in adult patients on veno-arterial extracorporeal life support (VA-ECLS) for refractory cardiogenic shock. In this study, we sought to compare outcomes between anti-factor Xa (FXa) and activated partial thromboplastin time (aPTT) strategies for UFH monitoring during VA-ECLS.MethodsThis is a single-center, retrospective review of VA-ECLS patients who received UFH in the cardiothoracic intensive care unit between July 2019 and November 2023. Standard protocol for UFH titration was aPTT goal of 45-60 sec (<i>n</i> = 52) before September 2021, then transitioned to FXa goal of 0.1-0.2 U/mL (<i>n</i> = 50) thereafter. Inverse probability of treatment weighting was used to balance baseline differences between cohorts.ResultsIn adjusted analyses, 89.3% of FXa patients and 76.0% of aPTT patients achieved goal range for their respective assay. Total UFH duration (4.0 vs 4.0 days, <i>p</i> = .239) and maximum weight-adjusted UFH dose (9.3 vs 9.4 U/hr/kg, <i>p</i> = .823) remained comparable between adjusted FXa and aPTT cohorts. Moreover, in-hospital mortality (50.3% vs 33.9%, <i>p</i> = .133), major bleeding events (20.6% vs 11.2%, <i>p</i> = .292), and thromboembolic events (30.1% vs 30.1%, <i>p</i> = .998) were not significantly different. Extracorporeal circuit thrombosis and cannula site bleeding were the most frequent events in both groups. Multivariate logistic regression found the FXa strategy was not a significant risk factor for the composite outcome of major bleeding or thromboembolism (OR [95% CI]: 1.539 [0.575, 4.116], <i>p</i> = .393).ConclusionsIn adult VA-ECLS patients at our institution, bleeding and thromboembolic complications occurred at a similar rate regardless of which UFH monitoring strategy was utilized. Further studies in larger and more institutionally diverse cohorts are warranted.

Authors

Institutions

Publication Details

Journal
Perfusion
Published
2024-12-26
DOI
https://doi.org/10.1177/02676591241309500
Citations
2
Primary Topic
Mechanical Circulatory Support Devices
Type
article
Field-Weighted Citation Impact
0.37
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Unfractionated heparin monitoring by anti-factor Xa versus activated partial thromboplastin time strategies during venoarterial extracorporeal life support

J. Fried, Yuji Kaku, Koji Takeda, Christine Yang et al.
2 citations
Perfusion
Mechanical Circulatory Support Devices
0.37
article

Unfractionated heparin monitoring by anti-factor Xa versus activated partial thromboplastin time strategies during venoarterial extracorporeal life support

J. Fried, Yuji Kaku, Koji Takeda, Christine Yang, Paul Kurlansky, Jonathan Hastie, Iris Feng, Tanner R. Powley, Lauren D. Sutherland
article en
2 citations

Abstract

IntroductionNo clear guidelines exist for unfractionated heparin (UFH) monitoring in adult patients on veno-arterial extracorporeal life support (VA-ECLS) for refractory cardiogenic shock. In this study, we sought to compare outcomes between anti-factor Xa (FXa) and activated partial thromboplastin time (aPTT) strategies for UFH monitoring during VA-ECLS.MethodsThis is a single-center, retrospective review of VA-ECLS patients who received UFH in the cardiothoracic intensive care unit between July 2019 and November 2023. Standard protocol for UFH titration was aPTT goal of 45-60 sec (<i>n</i> = 52) before September 2021, then transitioned to FXa goal of 0.1-0.2 U/mL (<i>n</i> = 50) thereafter. Inverse probability of treatment weighting was used to balance baseline differences between cohorts.ResultsIn adjusted analyses, 89.3% of FXa patients and 76.0% of aPTT patients achieved goal range for their respective assay. Total UFH duration (4.0 vs 4.0 days, <i>p</i> = .239) and maximum weight-adjusted UFH dose (9.3 vs 9.4 U/hr/kg, <i>p</i> = .823) remained comparable between adjusted FXa and aPTT cohorts. Moreover, in-hospital mortality (50.3% vs 33.9%, <i>p</i> = .133), major bleeding events (20.6% vs 11.2%, <i>p</i> = .292), and thromboembolic events (30.1% vs 30.1%, <i>p</i> = .998) were not significantly different. Extracorporeal circuit thrombosis and cannula site bleeding were the most frequent events in both groups. Multivariate logistic regression found the FXa strategy was not a significant risk factor for the composite outcome of major bleeding or thromboembolism (OR [95% CI]: 1.539 [0.575, 4.116], <i>p</i> = .393).ConclusionsIn adult VA-ECLS patients at our institution, bleeding and thromboembolic complications occurred at a similar rate regardless of which UFH monitoring strategy was utilized. Further studies in larger and more institutionally diverse cohorts are warranted.

PerfusionVol. 40(7)
Columbia University Irving Medical Center (US), Columbia University (US)
Responsible consumption and production
Openalex Percentile: Top 41%
Mechanical Circulatory Support Devices
0.37
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.